What is it about?
The current review summarizes practical challenges in the management of oral anticoagulation with emphasis on the risk assessment tools, elderly or underweight patients, cancer patients, impact of chronic kidney disease, liver cirrhosis and thrombocytopenia in the context of bleeding risk in AF patients. Key
Featured Image
Photo by Steve Johnson on Unsplash
Why is it important?
To improve the safety of anticoagulation in the era of non- vitamin K antagonist oral anticoagulants (NOAC, or direct oral anticoagulants [DOACs], including dabigatran, rivaroxaban, apixaban, and edoxaban), specific demographic, clinical, and laboratory variables should be considered.
Perspectives
Overall, NOACs were comparable or superior to VKAs in most patients with AF as shown in RCTs and observational studies. Individualization of anticoagulant therapy based on benefit and safety profiles as well as patient characteristics should be considered in particular in AF patients at elevated risk of bleeding, such as the elderly patients with several co-morbidities and those with cancer.
Leszek Drabik
Uniwersytet Jagiellonski w Krakowie
Read the Original
This page is a summary of: Bleeding in anticoagulated patients with atrial fibrillation: practical considerations, Polish Archives of Internal Medicine, January 2020, Towarzystwo Internistow Polskich/Polish Society of Internal Medicine,
DOI: 10.20452/pamw.15136.
You can read the full text:
Resources
Contributors
The following have contributed to this page
